Where Will Exxon Stock Be in 5 Years?
For sure Exxon Mobil (NYSE: XOM) is no hyped-up AI…
Sell
34
BHC.TO Quote, Financials, Valuation and Earnings
Last price:
$6.66
Seasonality move
:
1.31%
Day range:
$6.53 - $6.72
52-week range:
$5.45 - $13.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.18x
P/B ratio:
--
Volume:
368.7K
Avg. volume:
363K
1-year change:
-22.83%
Market cap:
$2.5B
Revenue:
$13.2B
EPS (TTM):
-$0.15
Analysts' Opinion
-
Consensus RatingBausch Health Companies has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.99, Bausch Health Companies has an estimated upside of 4.89% from its current price of $6.66.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.99 representing 100% downside risk from its current price of $6.66.
Fair Value
-
According to the consensus of 5 analysts, Bausch Health Companies has 4.89% upside to fair value with a price target of $6.99 per share.
BHC.TO vs. S&P 500
-
Over the past 5 trading days, Bausch Health Companies has overperformed the S&P 500 by 7.66% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Bausch Health Companies does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bausch Health Companies has grown year-over-year revenues for 11 quarters straight. In the most recent quarter Bausch Health Companies reported revenues of $3.2B.
Earnings Growth
-
Bausch Health Companies earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Bausch Health Companies reported earnings per share of -$0.23.
Enterprise value:
33B
EV / Invested capital:
1.08x
Price / LTM sales:
0.18x
EV / EBIT:
15.31x
EV / Revenue:
2.44x
PEG ratio (5yr expected):
-0.04x
EV / Free cash flow:
19.72x
Price / Operating cash flow:
1.47x
Enterprise value / EBITDA:
8.47x
Gross Profit (TTM):
$9.6B
Return On Assets:
-0.15%
Net Income Margin (TTM):
-0.42%
Return On Equity:
--
Return On Invested Capital:
-0.19%
Operating Margin:
12.93%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $10.8B | $12.1B | $13.5B | $2.9B | $3.2B | |
| Gross Profit | $7.6B | $8.6B | $9.6B | $2B | $2.2B | |
| Operating Income | $1.7B | $2.3B | $2.6B | $396.3M | $418.3M | |
| EBITDA | $3.4B | $3.1B | $3.9B | $816.9M | $842.3M | |
| Diluted EPS | -$1.35 | -$1.67 | -$0.15 | -$0.23 | -$0.23 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $6.8B | $7.3B | $5.7B | $7.3B | $8.2B | |
| Total Assets | $38.1B | $36.3B | $34.4B | $36.4B | $37.8B | |
| Current Liabilities | $6.2B | $6B | $5.3B | $6B | $6.1B | |
| Total Liabilities | $38.3B | $36.5B | $34.2B | $36.7B | $38.1B | |
| Total Equity | -$156.5M | -$176M | $196.1M | -$235.6M | -$343.4M | |
| Total Debt | $30B | $28.9B | $27.9B | $29.9B | $30.8B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$657.6M | $1.5B | $2.2B | $284.4M | $302.2M | |
| Cash From Investing | -$428.2M | -$2.9B | -$708.8M | -$98.4M | -$186.2M | |
| Cash From Financing | -$1.4B | $1.7B | -$938M | -$458.3M | -$209.1M | |
| Free Cash Flow | -$1B | $1.1B | $1.7B | $172.6M | $124.6M | |
BHC.TO
Sector
Market Cap
$2.5B
$33.9M
Price % of 52-Week High
48.47%
46.67%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-22.83%
-37.84%
Beta (5-Year)
0.321
0.633
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$6.36
200-day SMA
Sell
Level
$9.68
Bollinger Bands (100)
Sell
Level
6.73 - 10.41
Chaikin Money Flow
Sell
Level
-35.2M
20-day SMA
Buy
Level
$6.37
Relative Strength Index (RSI14)
Buy
Level
51.87
ADX Line
Buy
Level
20.36
Williams %R
Sell
Level
-8.3969
50-day SMA
Sell
Level
$6.89
MACD (12, 26)
Sell
Level
-0.16
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Neutral
Level
40M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.0341)
Sell
CA Score
(Annual)
Level (-2.5613)
Buy
Beneish M-Score
(Annual)
Level (-2.6347)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (8.4185)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
Stock Forecast FAQ
In the current month, BHC.TO has received 0 Buy ratings 5 Hold ratings, and 0 Sell ratings. The BHC.TO average analyst price target in the past 3 months is $6.99.
-
Where Will Bausch Health Companies Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bausch Health Companies share price will rise to $6.99 per share over the next 12 months.
-
What Do Analysts Say About Bausch Health Companies?
Analysts are divided on their view about Bausch Health Companies share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bausch Health Companies is a Sell and believe this share price will drop from its current level to $6.99.
-
What Is Bausch Health Companies's Price Target?
The price target for Bausch Health Companies over the next 1-year time period is forecast to be $6.99 according to 5 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is BHC.TO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bausch Health Companies is a Hold. 5 of 5 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of BHC.TO?
You can purchase shares of Bausch Health Companies via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bausch Health Companies shares.
-
What Is The Bausch Health Companies Share Price Today?
Bausch Health Companies was last trading at $6.66 per share. This represents the most recent stock quote for Bausch Health Companies. Yesterday, Bausch Health Companies closed at $6.66 per share.
-
How To Buy Bausch Health Companies Stock Online?
In order to purchase Bausch Health Companies stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Will Dollar General Stock Go?
Shares of Dollar General (NYSE:DG) have risen significantly in recent…
How High Can Planet Labs Go Now?
Planet Labs (NYSE:PL) has been a much-talked-about stock for years,…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
64
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
85
ASTS alert for Jun 10
AST SpaceMobile [ASTS] is up 1.95% over the past day.
Buy
69
CCJ alert for Jun 10
Cameco [CCJ] is down 1.78% over the past day.
Buy
73
AGX alert for Jun 10
Argan [AGX] is down 0.67% over the past day.
